DURECT is focusing its efforts on therapeutic areas with significant unmet need, including diseases with no approved treatments like alcoholic hepatitis (AH) and non-alcoholic steatohepatitis (NASH). The men and women of DURECT strive to fulfill a fundamental promise to patients, physicians, corporate partners, and investors: create best-in-class pharmaceutical products with enduring value—measured most directly by their potential to make real, palpable differences in the lives of those who need them.